Skip to main content
OpenTrials
Completed

NCT Number: NCT02154126

PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor

The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements (YSI glucose analyzer). The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Academic Medical Centre

Amsterdam, 1105AZ, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects meeting all of the following inclusion criteria will be included in this study:

  • Males and females ≥18 years of age
  • Clinically confirmed diagnosis of diabetes mellitus for a duration of 1 year and uses insulin therapy for their diabetes management (including subjects on insulin pump therapy)
  • Subject has signed an informed consent document and is willing to comply with protocol requirements

Exclusion criteria

Subjects meeting any of the following exclusion criteria will be excluded from this study:

  • History of severe hypoglycemia in the last 6 months prior to study start, defined as hypoglycemia resulting in loss of consciousness or seizure
  • Diabetic ketoacidosis in the past 6 months
  • Any condition preventing or complicating the placement, operation or removal of the Sensor including upper extremity deformities or skin condition.
  • Any medical condition or illness that in the judgment of the investigator might interfere with the procedures, results or compliance during the course of this investigation, or increase the risk of induced hypoglycemia or repeated blood testing including significantly impaired hepatic function and renal failure
  • Known microvascular (diabetic) complications, including active proliferative diabetic retinopathy or macular edema, active non-proliferative retinopathy, diabetic nephropathy including active retinopathy
  • Hematocrit >50% or <30%
  • Females lactating or pregnant or intending to become pregnant during the course of the investigation
  • A condition requiring or likely to require magnetic resonance imaging

Treatment and study plan

Continuous Glucose Monitoring Device (Senseonics)

Device

Primary outcomes

  1. Accuracy (mean absolute relative difference) compared to be reference device should be less than 20%

    Time frame: 90 days

    To determine accuracy of the Senseonics CGM System measurements over successive periods of 30 days of Sensor use through 180 days post-insertion.

Sponsors and collaborators

Lead sponsor

Senseonics, Inc.

Industry

Registry information

Acronym: PRECISE

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jun 3, 2014
Registry last updated
Jan 21, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.